← Human Trials & Peer-Reviewed Studies
Magnesium citrate monotherapy improves restless legs syndrome symptoms and multiple suggested immobilization test scores in an open-label pilot study.
Plain-language guide to PMID 38738598 (2024): open-label and pilot clinical trial of Vitamin D, K2, Magnesium and Zinc in 10 women.
Key Facts
- PMID
- 38738598
- Journal
- Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine
- Year
- 2024
- Study type
- Clinical Trial
- Authors
- Gorantla S et al. (3 authors)
- DOI
- 10.5664/jcsm.11206
- Registered trial
- NCT04462796
What This Study Did, in Plain Language
What Was Tested
This clinical trial looks at Vitamin D, K2, Magnesium and Zinc.
Registry: ClinicalTrials.gov; Name: The Effect of Magnesium Citrate Supplementation in Restless Legs Syndrome (RLS); URL: https://clinicaltrials.gov/ct2/show/study/NCT04462796; Identifier: NCT04462796.
Gorantla S, Ravisankar A, Trotti LM.
Who Took Part
The study group was 10 women.
PubMed indexes the participants as adults and middle-aged adults, both men and women.
How the Study Was Run
The design is described as open-label and pilot.
Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the women and staff both knew the treatment.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
Paired t tests and Wilcoxon signed-rank tests were used for data analysis.
Pearson and Spearman's analyses assessed the association between magnesium levels and restless legs syndrome variables.
What Was Measured
The subject headings attached to it are Citric Acid, Magnesium, Organometallic Compounds, Pilot Projects, Quality of Life and Restless Legs Syndrome.
Author keywords: International Restless Legs Syndrome Study Group Rating Scale, magnesium citrate, magnesium supplementation and multiple suggested immobilization test.
What This Means in Plain Language
The paper is an open-label and pilot study of Vitamin D, K2, Magnesium and Zinc in 10 women.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2024 (Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine), a journal based in Switzerland.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.